Cornea Services, LJ Eye Institute, Ambala, Haryana, India.
Oculoplasty Services, LJ Eye Institute, Ambala, Haryana, India.
Indian J Ophthalmol. 2018 May;66(5):697-699. doi: 10.4103/ijo.IJO_904_17.
Botulinum toxin A (BTA) injections into lacrimal gland are being used for refractory epiphora due to intractable lacrimal disorders with success rates reported from 18% to 86%. Most common side effects are transient ptosis and diplopia. We report a case of a 59-year-old female injected with 2.5 units of BTA injection in each lacrimal gland for functional epiphora. The patient had a history of herpes simplex viral keratitis that was quiescent for more than 2 years. After 3 weeks, she developed reactivation of viral keratitis bilaterally, which was successfully managed with antivirals and topical steroids. Reactivation of quiescent herpes simplex keratitis is a possibility after lacrimal gland BTA and caution should be exercised in such cases.
肉毒杆菌毒素 A(BTA)注射到泪腺中,用于治疗因难治性泪液疾病导致的难治性溢泪,成功率报告为 18%至 86%。最常见的副作用是短暂的上睑下垂和复视。我们报告了一例 59 岁女性,在每侧泪腺中注射 2.5 单位的 BTA 注射剂用于治疗功能性溢泪。该患者有单纯疱疹病毒性角膜炎病史,已超过 2 年处于静止状态。3 周后,她双侧出现病毒性角膜炎复发,经抗病毒和局部类固醇治疗后成功控制。泪腺 BTA 后静止性单纯疱疹性角膜炎的复发是一种可能,因此在这种情况下应谨慎行事。